Trial · NCT07449481
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
NCT07449481, Phase 2, Withdrawn, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors. Trials, record NCT07449481. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07449481
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
- NCT number
- NCT07449481
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Malignant Solid Tumor, Brain Metastasis
- Interventions
- Utidelone, Bevacizumab
- First posted
- 2026-03-04
- Last updated
- 2026-07-16
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CNS-ORR | Primary outcomes assessed from baseline until the end of study, up to 48 months. | The best efficacy evaluation observed during the entire process from enrollment to the assessment of all central nervous system target lesions according to the RANO-BM criteria was the proportion of patients who achieved complete response (CR) and partial response (PR) among the total number of evaluable patients. |
| Secondary | CNS-CBR | Secondary outcomes assessed from baseline until the end of study, up to 48 months. | The percentage of patients who achieved complete response (CR), partial response (PR), or disease stability (SD) for all central nervous system target lesions as evaluated according to the RANO-BM criteria. |
| Secondary | ORR | Secondary outcomes assessed from baseline until the end of study, up to 48 months.From February 2026 to February 2030 | According to the RECIST 1.1 standard, the proportion of patients who achieved the best efficacy evaluation of CR or PR (complete response or partial response) from the time of enrollment to the occurrence of disease progression among all evaluable patients. |
| Secondary | CNS-PFS | Secondary outcomes assessed from baseline until the end of study, up to 48 months. | |
| Secondary | PFS | Secondary outcomes assessed from baseline until the end of study, up to 48 months.From February 2026 to February 2030 | |
| Secondary | Extracranial Objective Response Rate (EC-ORR) | Secondary outcomes assessed from baseline until the end of study, up to 48 months.From February 2026 to February 2030 | According to the RECIST 1.1 standard, the proportion of patients who achieved the best efficacy evaluation of CR or PR (complete response or partial response) from the time of enrollment to the occurrence of disease progression among all evaluable extracranial patients. |
| Secondary | Extracranial progression-free survival (PFS) | Secondary outcomes assessed from baseline until the end of study, up to 48 months.From February 2026 to February 2030 | |
| Secondary | OS | Secondary outcomes assessed from baseline until the end of study, up to 48 months.From February 2026 to February 2030 | |
| Secondary | adverse event | Secondary outcomes assessed from baseline until the end of study, up to 48 months.From February 2026 to February 2030 | AE, SAE and laboratory tests were analyzed and summarized based on the severity. The safety evaluation population included all patients who had received at least one dose of utidefron and had safety records after the medication. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07449481
GET https://conductscience.org/api/trials/v1/NCT07449481/registered